Literature DB >> 684036

Multicompartmental analysis of serum, urine and bile concentrations of rifampicin and desacetyl-rifampicin in subjects treated for one week.

G Acocella, R Mattiussi, G Segre.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 684036     DOI： 10.1016/s0031-6989(78)80021-6

Source DB:  PubMed          Journal:  Pharmacol Res Commun        ISSN： 0031-6989


× No keyword cloud information.
  14 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

2.  Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.

Authors:  Justin J Wilkins; Radojka M Savic; Mats O Karlsson; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

3.  Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.

Authors:  K E Dooley; E E Bliven-Sizemore; M Weiner; Y Lu; E L Nuermberger; W C Hubbard; E J Fuchs; M T Melia; W J Burman; S E Dorman
Journal:  Clin Pharmacol Ther       Date:  2012-05       Impact factor: 6.875

Review 4.  Clinical implications of enzyme induction and enzyme inhibition.

Authors:  B K Park; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

5.  Pharmacokinetic studies of cimetidine and ranitidine before and after treatment in peptic ulcer patients.

Authors:  G W Mihaly; D B Jones; J A Anderson; R A Smallwood; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

6.  Rifampicin kinetics in undernutrition.

Authors:  K Polasa; K J Murthy; K Krishnaswamy
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

7.  Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects.

Authors:  S A Ward; G W Mihaly; G Edwards; S Looareesuwan; R E Phillips; P Chanthavanich; D A Warrell; M L Orme; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

8.  Pharmacokinetics of oral and intravenous rifampicin during chronic administration.

Authors:  U Loos; E Musch; J C Jensen; G Mikus; H K Schwabe; M Eichelbaum
Journal:  Klin Wochenschr       Date:  1985-12-02

9.  Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepine.

Authors:  W G Rapeport; G T McInnes; G G Thompson; G Forrest; B K Park; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics of rifampicin.

Authors:  G Acocella
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.